Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/32554
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWeerawat Manosuthien_US
dc.contributor.authorChonlaphat Sukasemen_US
dc.contributor.authorAroon Lueangniyomkulen_US
dc.contributor.authorWiroj Mankatithamen_US
dc.contributor.authorSupeda Thongyenen_US
dc.contributor.authorSamruay Nilkamhangen_US
dc.contributor.authorSukanya Manosuthien_US
dc.contributor.authorSomnuek Sungkanuparphen_US
dc.contributor.otherThailand Ministry of Public Healthen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-10-19T05:33:36Z-
dc.date.available2018-10-19T05:33:36Z-
dc.date.issued2013-02-01en_US
dc.identifier.citationAntimicrobial Agents and Chemotherapy. Vol.57, No.2 (2013), 1019-1024en_US
dc.identifier.issn10986596en_US
dc.identifier.issn00664804en_US
dc.identifier.other2-s2.0-84872869312en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84872869312&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/32554-
dc.description.abstractComprehensive information on the effects of cytochrome P450 2B6 (CYP2B6) polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in HIV/tuberculosis-coinfected (HIV/TB) patients is unavailable.A total of 139 HIV/TB adults, 101 of whom received a rifampin-containing anti-TB regimen, were prospectively enrolled to receive efavirenz (600 mg)/ tenofovir/lamivudine.Nine single nucleotide polymorphisms (SNPs) within CYP2B6 were genotyped.Plasma efavirenz concentrations were measured at 12 weeks.The median (interquartile range [IQR]) efavirenz concentration was 2.3 (1.4 to 3.9) mg/liter.The SNPs (frequencies of heterozygous and homozygous mutants) were 64C>T (10% and 1%), 499C>G (0% and 0%), 516G>T (47% and 8%), 785A>G (54% and 10%), 1375A>G (0% and 0%), 1459C>T (3% and 0%), 3003C>T (44% and 27%), 18492T>C (39% and 6%), and 21563C>T (57% and 5%).The four most frequent CYP2B6 haplotypes identified were *1/*6 (41%), *1/*1 (35%), *1/*2 (7%), and *6/*6 (7%).The heterozygous/homozygous mutation associated with low efavirenz concentrations was 18492T>C (P<0.001), and those associated with high efavirenz concentrations were 516G>T, 785A>G, and 21563C>T (all P<0.05).Haplotype *1/*1 was associated with low efavirenz concentrations, and *6/*6, *1/*6, and *5/6 were associated with high efavirenz concentrations.As shown by multivariate analysis, low efavirenz concentrations were significantly associated with the *1/*1 haplotype (beta=-1.084, P=.027) and high body weight (beta=-0.076, P=.002).In conclusion, pharmacogenetic markers of CYP2B6 have the greatest impact with respect to inducing low plasma efavirenz concentrations in HIV/TB Thai patients.Copyright © 2013, American Society for Microbiology.All Rights Reserved.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84872869312&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleImpact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patientsen_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.1128/AAC.02023-12en_US
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.